Reduction of Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis Treated With Raloxifene&lt;SUBTITLE&gt;Results From a 3-Year Randomized Clinical Trial&lt;/SUBTITLE&gt;

Ettinger, Bruce

doi:10.1001/jama.282.7.637

Public

Reduction of Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis Treated With Raloxifene<SUBTITLE>Results From a 3-Year Randomized Clinical Trial</SUBTITLE>

Published in JAMA • Aug 18, 1999

Authors:

Bruce Ettinger

Abstract

CONTEXT: Raloxifene hydrochloride, a selective estrogen receptor modulator, prevents bone loss in postmenopausal women, but whether it reduces fracture risk in these women is not known. OBJECTIVE: To determine the effect of raloxifene therapy on risk of vertebral and nonvertebral fractures. DESIGN: ...

Subject

Medicine

Raloxifene

Osteoporosis

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!